← Back to Search

HEREDITARY RISK for Lung Cancer

N/A
Recruiting
Led By Sapna Syngal, MD
Research Sponsored by Dana-Farber Cancer Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 years
Awards & highlights

Summary

This research study is creating a way to collect and store specimens and information from participants who may be at an increased risk of developing cancer, or has been diagnosed with an early phase of a cancer or a family member who has a family member with a precursor condition for cancer. * The objective of this study is to identify exposures as well as clinical, molecular, and pathological changes that can be used to predict early development of cancer, malignant transformation, and risks of progression to symptomatic cancer that can ultimately be fatal. * The ultimate goal is to identify novel markers of early detection and risk stratification to drive potential therapeutic approaches to intercept progression to cancer.

Eligible Conditions
  • Lung Cancer
  • Breast Cancer
  • Cancer Predisposition Syndrome
  • Endometrial Neoplasia
  • Osteochondromas
  • Vulvar Intraepithelial Neoplasia
  • Nephrogenic Rest Syndrome
  • Adenomatous Hyperplasia
  • Oral Precancerous Diseases
  • Cervical and Endocervical Carcinoma
  • Spitz Nevus
  • Smoking History
  • Liver Cirrhosis
  • Adult Cancer Survivors
  • Cancer Risk
  • Carcinogens
  • Osteochondroma
  • Bladder Cancer
  • Cancer Predisposition
  • Childhood Cancer Survivors
  • Barrett's Esophagus
  • Pancreatic Lesions
  • Tubal Intraepithelial Carcinoma
  • Prostate Cancer
  • Melanoma
  • Giant Cell Tumor
  • Blood Cancers
  • Colonic Adenomas
  • Non-alcoholic Fatty Liver Disease
  • Lung Nodules

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Malignant Neoplasms

Trial Design

4Treatment groups
Experimental Treatment
Group I: PRECURSOR LESIONSExperimental Treatment1 Intervention
Participants will also be asked to complete an intake survey that will include questions about demographics, medical history and family history data. Tissue samples will be collected during a routine visit. Participants will be asked to donate any of the following tissue types: * Blood * Buccal swab (saliva) or mouthwash * Urine * Stool * Biopsy or surgical tissue (i.e., bone marrow) * Bodily fluids * Other tissues
Group II: HEREDITARY RISKExperimental Treatment1 Intervention
Participants will also be asked to complete an intake survey that will include questions about demographics, medical history and family history data. Tissue samples will be collected during a routine visit. Participants will be asked to donate any of the following tissue types: * Blood * Buccal swab (saliva) or mouthwash * Urine * Stool * Biopsy or surgical tissue (i.e., bone marrow) * Bodily fluids * Other tissues
Group III: FAMILY MEMBERSExperimental Treatment1 Intervention
These family members will be identified by the patients participating in the study. Blood, buccal cells, or saliva or oral rinses will be collected in one of three ways from family members of patients (i) at the time of consent; (ii) via a mailed blood kit or saliva kit; or (iii) at a separate appointment scheduled by the consented participant
Group IV: EXPOSED HIGH RISKExperimental Treatment1 Intervention
Participants will also be asked to complete an intake survey that will include questions about demographics, medical history and family history data. Tissue samples will be collected during a routine visit. Participants will be asked to donate any of the following tissue types: * Blood * Buccal swab (saliva) or mouthwash * Urine * Stool * Biopsy or surgical tissue (i.e., bone marrow) * Bodily fluids * Other tissues

Find a Location

Who is running the clinical trial?

Dana-Farber Cancer InstituteLead Sponsor
1,100 Previous Clinical Trials
348,097 Total Patients Enrolled
Sapna Syngal, MDPrincipal InvestigatorDana-Farber Cancer Institute
Irene C Ghobrial, MDPrincipal InvestigatorDana-Farber Cancer Institute
1 Previous Clinical Trials
52 Total Patients Enrolled
~2571 spots leftby Mar 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top